Novo Nordisk A/S $NVO Shares Bought by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 112.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 23,699 shares of the company’s stock after acquiring an additional 12,530 shares during the period. Moloney Securities Asset Management LLC’s holdings in Novo Nordisk A/S were worth $1,315,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. SG Americas Securities LLC increased its stake in shares of Novo Nordisk A/S by 2,101.5% in the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after acquiring an additional 2,274,925 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of Novo Nordisk A/S by 101.4% in the second quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock valued at $170,845,000 after purchasing an additional 1,246,467 shares during the period. DAVENPORT & Co LLC increased its position in Novo Nordisk A/S by 54.8% during the third quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock worth $146,644,000 after purchasing an additional 935,468 shares during the last quarter. Sustainable Growth Advisers LP raised its stake in Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after purchasing an additional 649,390 shares during the period. Finally, Baird Financial Group Inc. boosted its holdings in Novo Nordisk A/S by 42.6% in the 2nd quarter. Baird Financial Group Inc. now owns 1,476,673 shares of the company’s stock valued at $101,920,000 after purchasing an additional 441,034 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA says it will target mass-marketed, unapproved compounded drug copies, which reduces the competitive threat from low-cost copycats and helped lift sentiment. Novo Nordisk shares rebound as FDA targets illegal drug copies – Reuters
• Positive Sentiment: Some analysts view the recent selloff as overdone and argue NVO’s strong cash flow, first-mover Wegovy advantages and promising pipeline (CagriSema) make the pullback a buying opportunity for long-term holders. Novo Nordisk: The Selloff Is A Blessing In Disguise – Seeking Alpha
• Positive Sentiment: Novo has announced it will pursue legal action against Hims & Hers over compounded Wegovy copies — a defensive step that could limit spread of low-cost alternatives if successful. Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding – Reuters
• Neutral Sentiment: Company disclosure shows trading by board members and executives — useful for monitoring insider behavior but not immediately directional. Trading in Novo Nordisk shares by board members, executives – GlobeNewswire
• Neutral Sentiment: Company declared a dividend (record/ex-dividend dates published) — supportive for income investors but not a cure for near-term volume/price headwinds.
• Negative Sentiment: Hims & Hers launched a $49–$99 compounded oral semaglutide offering, sharply undercutting Wegovy’s price and triggering market panic about pricing erosion and access to cheap compounding alternatives. Hims and Hers Health launches copy of Wegovy pill at $49 – Reuters
• Negative Sentiment: Citi warns that inability to curb compounded semaglutide use is a lingering risk to Novo’s pricing power and investor sentiment. Citi flags lingering risks to Novo despite strong weight-loss portfolio – Proactive Investors
• Negative Sentiment: Competitive dynamics: Eli Lilly’s strong guidance and manufacturing scale are shifting market share and investor preference toward Lilly, increasing near-term pressure on Novo’s revenue outlook. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles – MarketBeat
• Negative Sentiment: Regional weakness: Ozempic sales in greater China fell for the first time, highlighting geographic and competitive pressures. Novo reports first Ozempic sales drop in greater China region – Reuters

Analyst Upgrades and Downgrades

NVO has been the topic of a number of research analyst reports. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, January 9th. Morgan Stanley reiterated an “underweight” rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Citigroup began coverage on Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a “neutral” rating on the stock. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday. Seven equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $56.07.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $47.71 on Friday. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The company has a fifty day simple moving average of $53.61 and a two-hundred day simple moving average of $53.85. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The company has a market cap of $213.03 billion, a price-to-earnings ratio of 13.75 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 4th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 23.63%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.